We then validated the potential role of TRAF3 as a tumor-immune suppressive mediator by injecting TRAF3KO1 (henceforth referred to as TRAF3KO) and ITB1 cells into NSG and WT mice and monitoring ascites development and the survival of the mice. Here, TRAF3 is linked to neoplasm.